IRVINE, CALIF., AND SAN JOSE, CALIF. (PRWEB) NOVEMBER 07, 2022
EmeritusDX and KDx Diagnostics announced today the partnership to provide the URO17 test for the detection of bladder cancer. URO17 is a non-invasive urine test with high sensitivity and negative predicted value (NPV) that can be used to determine the status of active bladder cancer and to improve patient diagnosis. This is also likely to improve the treatment path as URO17 is also now available as a Laboratory Developed Test (LDT) in the United States. EmeritusDX will offer URO17 testing to Urology practices across the country. …read more
